The term "rare disease" suggests something unknowable, a medical enigma destined to remain unsolved. Yet Dr. Laurel Crosby Delof from Stanford's Genome Technology Center challenges this framing, proposing instead that these conditions represent "solvable mysteries" rather than inherently rare phenomena. At March's recent GenAI x Rare Disease event at UC Berkeley, she introduced a compelling reframing: "Obscuropathy" -- conditions where there is an answer, we just don't know what it is yet.
The Labyrinth of the Diagnostic Odyssey
Patients with undiagnosed conditions face an exhausting "diagnostic odyssey." Research reveals that the average diagnostic journey spans nearly five years and involves visits to seven or more physicians before reaching an accurate diagnosis.
Multiple systemic barriers contribute to these delays:
- Limited Provider Familiarity: Doctors have specialized training but rarely encounter these specific conditions among thousands that exist
- Reactive Systems: Medical professionals require extreme illness severity before ordering genetic testing
- Institutional Silos: Limited awareness among general practitioners, insufficient integrated care teams, and specialist shortages compound the problem
Dr. Crosby observed that the current system is "built this way," creating deliberate separation between patients, clinicians, and researchers -- precisely those who must collaborate to solve medical mysteries.
Researchers Facing Their Own Walls
Scientists encounter substantial obstacles when pursuing rare disease research:
Data Access Challenges: Navigating HIPAA privacy regulations, obtaining ethics approvals, and establishing data transfer agreements creates significant administrative burden. Unlike clinicians who communicate freely with patients, researchers operate under strict protocols that inadvertently slow scientific progress.
Funding Barriers: Securing research funding for rare disease investigations proves exceptionally difficult. Many researchers need preliminary results to apply for grants, yet obtaining those results requires existing funding -- a catch-22 that forces many to study laboratory cells rather than actual patients.
A New Framework: Accuracy and Efficiency
Dr. Crosby proposed two strategic pillars for improvement:
Accuracy (Precision Data): Moving beyond symptom-based labels requires examining each patient's complete story -- symptoms, diet, exposures, genetics, biomarkers, and detailed biological data. Real diagnosis demands precision rather than generalization.
Efficiency (Communication and Interaction): Information must reach the right people quickly. Researchers analyzing complex data should provide clear insights enabling faster diagnoses. Effective teamwork requires streamlined information flow.
Solving One Case at a Time
Dr. Crosby envisions systematic progress through methodical case resolution: "If you solve the case and I solve a case and we all solve a case, we're going to get through all 10,000 of these rare diseases."
Each solved case becomes a recognizable pattern, a validated model the community can build upon. She imagines a future resembling "GitHub for medicine," where validated diagnostic models and underlying logic are shared openly, enabling collective knowledge building similar to open-source software development and initiatives like the Global Alliance for Genomics and Health (GA4GH).
Data-Driven Decision Making
When questioned about prevention versus treatment or health trends like intermittent fasting, Dr. Crosby consistently emphasized: "Show me the data." Generic advice often fails individuals. Understanding specific biology -- genetics, exposures, and unique circumstances -- proves essential for personalized solutions.
Marching Toward Clarity with AI as an Ally
Dr. Crosby's analysis of systemic and data challenges aligns perfectly with AI's potential contributions: aggregating complex patient information, identifying subtle patterns humans might miss, facilitating cross-disciplinary communication, and potentially building the collaborative medical platform envisioned.
March commits to fostering communities where patient observations are valued and where collective experience converges with cutting-edge research. Together, communities can transform the diagnostic journey from a frustrating odyssey into a pathway toward genuine answers and improved health outcomes.